Liquid Biotech USA is a biotechnology company with a unique and powerful approach to diagnosing cancer; our technology can detect cancer at early stages of the disease.

 

Senior Management

Philip Sass, PhD

Philip Sass, PhD

Chairman, President, CEO

As Chairman, President and CEO of Liquid Biotech USA, Inc., Philip M. Sass, PhD recently led a financing round of $3M to support the Company by allowing it to develop its proprietary cancer diagnostic and gene discovery platform.

Dr. Philip M. Sass is a Senior Executive with broad experience in the pharmaceutical and biotechnology area. During his career he has held positions of Chief Operating Officer and Executive Vice President of Morphotek Inc., a biotechnology company that specialized in developing biologics for the treatment of oncology, infectious and autoimmune diseases, as well as Executive Vice President and Head, Biopharmaceutical Development at Eisai. As a senior executive and co-founder of Morphotek Inc., he was involved with developing a business model and plan, obtaining $2M is seed funding from Angel investors followed by raising an additional $86M over three venture backed institutional financing rounds to successfully exit and sell the company to Eisai for $325M.

Dr. Sass graduated from University of Miami, Coral Gables, Florida, with a BS degree in Biochemistry and received a Ph.D. in Biochemistry from Indiana University, Bloomington, Indiana. He was a Damon Runyon-Walter Winchell Cancer fund Fellow at Cold Spring Harbor Laboratory where he trained in both genetics and cancer biology. He has published more than 30 scientific manuscripts and has over 40 US patents that have been issued.

Jeffrey M. Janco

Jeffrey M. Janco

Executive Vice President, COO, Board Member

As EVP and COO of Liquid Biotech USA, Inc., Jeffrey M. Janco recently led a financing round of $3M to support the Company by allowing it to develop its proprietary cancer diagnostic and gene discovery platform.

Jeffrey M. Janco is a senior level executive with 30 years of extensive Operations experience at Medical Nutrition USA, Inc., which is engaged in the development and distribution of proprietary Nutrition-Medicine products for the nutritionally at risk. As EVP and COO, he had a demonstrated record of success by greatly enhancing supply chain productivity and efficiency of operations, including implementing systems and internal controls. Additional responsibilities included handling the Company’s day-to-day operating activities. Prior positions at the Company included SVP, Principal Financial & Accounting Officer, Treasurer and VP of Human Resources. The public Company was acquired by Group Danone (“Dannon”) in 2010. Mr. Janco assumed additional responsibilities for Nutricia, their Medical Nutrition Division, which included the spearheading of global operations initiatives for the business unit in safety and crisis management.

More recently, Mr. Janco was Vice President, Operations for Novel Ingredient Services, a manufacturer and distributor of premium quality raw materials; specifically nutraceuticals and botanicals. He developed and implemented an extensive OSHA program for manufacturing and warehousing/distribution.

Mr. Janco is a graduate of the University of Miami, Coral Gables, FL and earned a Bachelor of Business Administration degree in Management.

Co-Founders

Jay F. Dorsey, MD, PhD

Jay F. Dorsey, MD, PhD

Co-Founder, Assistant Professor, University of Pennsylvania

Jay F. Dorsey, MD, PhD is a co-Founder of Liquid Biotech USA. He is currently an Assistant Professor of Radiation Oncology at the University of Pennsylvania and an NIH R01-funded Physician-Scientist with an active translational research laboratory focused on circulating tumor biomarkers and development of novel anti-cancer therapies and theranostic agents. He is a practicing Radiation Oncologist with clinical expertise in CNS malignancies and stereotactic radiosurgery. Dr. Dorsey graduated from University of Florida, Gainesville, Florida, with a B.S. degree in Chemical Engineering and received a M.S. in Chemical Engineering from the University of South Florida (USF), Tampa, FL. He completed an M.D. and Ph.D. from USF and conducted his dissertation research in cancer signal transduction at the Moffitt Cancer Center’s Molecular Oncology Program, where he was part of one of the first research groups to characterize dual Src/Bcr-Abl tyrosine kinase inhibitors as effective against Chronic Myelogenous Leukemia (CML), which ultimately led to the development of 2nd generation CML drugs such as Dasatinib and Nilotinib (effective against imatinib-resistant CML). He completed an American Board of Radiology (ABR)-sponsored research pathway residency in Radiation Oncology at the Hospital of the University of Pennsylvania and the Abramson Cancer Center and is a board-certified Radiation Oncologist. He was an ASCO Young Investigator Awardee, recipient of a Burroughs Wellcome Fund Career Award for Medical Scientists (CAMS), and an NIH-sponsored K08 Career Award. Dr. Dorsey has expertise in the areas of CTCs, nanoparticle theranostics, radiation biology, drug discovery, molecular oncology, experimental therapeutics, and early phase clinical trials.”

Dr. Stephen M. Hahn

Dr. Stephen M. Hahn

Co-Founder, Professor, Radiation Oncology Division Head and Department Chair, Division of Radiation Oncology, MD Anderson Cancer Center

Dr. Stephen M. Hahn is an international leader in the field of Radiation Oncology. Dr. Hahn is triple-Board Certified (Radiation Oncology, Medical Oncology and Internal Medicine) and especially renowned for his expertise in lung cancer and sarcoma. A physician-scientist with a long history of successfully attracting NIH funding, Dr. Hahn’s research focuses on proton therapy, the molecular aspects of the tumor microenvironment, aberrant cell signaling in cancer cells, and tumor biomarkers. Dr. Hahn is a member of the board of directors for the American Society for Radiation Oncology, which also designated him a Fellow in 2013. In addition, he serves as a trustee for the American Board of Radiology. He is course director for the Flims Course for Clinical Trials Methodology, an educational program sponsored by various international cancer organizations that introduces junior clinical oncologists to the principles of good clinical trial design. He also is a faculty member in the Vail Course for Clinical Trials Methodology, sponsored by the American Association for Cancer Research and the American Society of Clinical Oncology. He has published over 170 scientific manuscripts.

Dr. Hahn earned his undergraduate degree from Rice University and his M.D. from Temple University in Philadelphia. He completed an internship and residency at the University of California Medical Centers-San Francisco, and a medical oncology fellowship and radiation oncology residency at the National Cancer Institute. He was previously the Henry K. Pancoast Professor and Chair of Radiation Oncology at the University of Pennsylvania where he established and led a state-of-the-art proton therapy center, increased NIH-funded research and clinical trials at the institution, and served in important university leadership roles. Dr. Hahn is now Professor and Department Chair, Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX, where he also leads the Division of Radiation Oncology as Division Head.

Gary D. Kao, MD, PhD

Gary D. Kao, MD, PhD

Co-Founder, Associate Professor, University of Pennsylvania

Gary D. Kao, MD, PhD is a co-Founder of Liquid Biotech USA. He is currently an Associate Professor of Radiation Oncology at the University of Pennsylvania, and a tenured Physician-Scientist dedicated towards making discoveries that lead to the most effective and least harmful treatment to the greatest number of cancer patients. Dr. Kao draws upon a skill-set crafted during the course of a twenty-year career as a Board-certified Radiation Oncologist and independent investigator on numerous private and NIH-funded grants building and leading translational research teams to pursue cutting edge problems. Dr. Kao graduated from Johns Hopkins University, with a B.A. degree in Philosophy, followed by the earning of a M.D. from Johns Hopkins School of Medicine. He completed residency training in Radiation Oncology at the Hospital of the University of Pennsylvania, earned board-certification by the American Board of Radiology (ABR), followed by a Ph.D. at the University of Pennsylvania. Dr. Kao has built the foundation for the proposed research by establishing close clinical and laboratory collaborations and developing expertise in techniques for dissecting cancer and cell biology and genetics.

Board of Directors

Philip Sass, PhD

Philip Sass, PhD

Chairman, President, CEO

As Chairman, President and CEO of Liquid Biotech USA, Inc., Philip M. Sass, PhD recently led a financing round of $3M to support the Company by allowing it to develop its proprietary cancer diagnostic and gene discovery platform.

Dr. Philip M. Sass is a Senior Executive with broad experience in the pharmaceutical and biotechnology area. During his career he has held positions of Chief Operating Officer and Executive Vice President of Morphotek Inc., a biotechnology company that specialized in developing biologics for the treatment of oncology, infectious and autoimmune diseases, as well as Executive Vice President and Head, Biopharmaceutical Development at Eisai. As a senior executive and co-founder of Morphotek Inc., he was involved with developing a business model and plan, obtaining $2M is seed funding from Angel investors followed by raising an additional $86M over three venture backed institutional financing rounds to successfully exit and sell the company to Eisai for $325M.

Dr. Sass graduated from University of Miami, Coral Gables, Florida, with a BS degree in Biochemistry and received a Ph.D. in Biochemistry from Indiana University, Bloomington, Indiana. He was a Damon Runyon-Walter Winchell Cancer fund Fellow at Cold Spring Harbor Laboratory where he trained in both genetics and cancer biology. He has published more than 30 scientific manuscripts and has over 40 US patents that have been issued.

Jeffrey M. Janco

Jeffrey M. Janco

EVP, COO, Board Member

As EVP and COO of Liquid Biotech USA, Inc., Jeffrey M. Janco recently led a financing round of $3M to support the Company by allowing it to develop its proprietary cancer diagnostic and gene discovery platform.

Jeffrey M. Janco is a senior level executive with 30 years of extensive Operations experience at Medical Nutrition USA, Inc., which is engaged in the development and distribution of proprietary Nutrition-Medicine products for the nutritionally at risk. As Executive Vice President and Chief Operations Officer, he had a demonstrated record of success by greatly enhancing supply chain productivity and efficiency of operations, including implementing systems and internal controls. Additional responsibilities included handling the Company’s day-to-day operating activities. Prior positions at the Company included SVP, Principal Financial & Accounting Officer, Treasurer and VP of Human Resources. The public Company was acquired by Group Danone (“Dannon”) in 2010. Mr. Janco assumed additional responsibilities for Nutricia, their Medical Nutrition Division, which included the spearheading of global operations initiatives for the business unit in safety and crisis management.

More recently, Mr. Janco was Vice President, Operations for Novel Ingredient Services, a manufacturer and distributor of premium quality raw materials; specifically nutraceuticals and botanicals. He developed and implemented an extensive OSHA program for manufacturing and warehousing/distribution.

Mr. Janco is a graduate of the University of Miami, Coral Gables, FL and earned a Bachelor of Business Administration degree in Management.

Yasunari Kashihara, M.Sc., M.B.A.

Yasunari Kashihara, M.Sc., M.B.A.

Board Member

Yasunari (Yas) Kashihara has more than 25 years of experience in the Japanese pharmaceutical industry as Vice President, Business Development, Oncolys BioPharma Inc. and President, Oncolys USA Inc.

He joined Oncolys BioPharma Inc. in 2007 and has been responsible for the business development and corporate planning. He led the company’s historical licensing deal with Bristol-Myers Squibb in 2010 on its HIV compound with total deal size of $286 million. Before joining Oncolys, Mr. Kashihara was a President and CEO of UMN Pharma Inc. and successfully managed the rapid growth of its business during the starting up period. He especially involved fund raising of more than $30 million and successfully initiated collaboration with Protein Sciences Corporation in Connecticut. Prior to that, he was a manager of licensing at Santen Pharmaceutical Co., Ltd., after serving as a pharmacological researcher at Ciba-Geigy Japan Limited (Novartis Pharma K.K.).

Mr. Kashihara received his B.Sc. and M.Sc. degree from Kyoto Pharmaceutical University and M.B.A. degree from Trinity College Dublin in Republic of Ireland.

Michael D. Poisel, MS, M.B.A.

Michael D. Poisel, MS, M.B.A.

Board Member

Since joining the University of Pennsylvania in 2009, Michael, Managing Director, PCI Ventures, has been building entrepreneurial programs for the university. He currently manages PCI Ventures, which includes UPstart, AppitUP, and UPadvisors.

The mission of UPSTART is to provide Penn faculty and staff with the means and support to launch businesses based on their promising research. Through the creation of the companies, UPSTART focuses the faculty member on applied research and building the commercial value of the technology to their benefit as well as the university and society in general. After the company is formed, UPSTART continues to assist in the development of the business by providing several additional entrepreneurial services including Addressable Market Analysis, Product Strategy Development, Fund Raising Assistance, Commercialization Grant Preparation and Management Team Recruitment.

In the past four years, UPSTART has initiated over 100 company projects of which many are now operating businesses.

Prior to Penn, Michael made investments in enterprise software and business services for NewSpring Capital, Apax Partners and GE Capital spanning more than ten years in private equity. He began his career in manufacturing operations for General Electric/Lockheed Martin and participated in the successful completion of several commercial and government satellite programs.

Michael graduated with honors in Mechanical Engineering from Rose-Hulman Institute of Technology, holds an M.S. in Systems Engineering from The Moore School of Engineering of the University of Pennsylvania, and has an M.B.A. in finance and entrepreneurial management from The Wharton School of Business of the University of Pennsylvania.